Evommune Doses First Patient in Phase 2b Migraine Trial for EVO756 After CSU Setback
EVMN is trading near its 52-week low of $10.47 (4.1% above the low) on light trading volume (0.4× avg).
Summary
Evommune has dosed the first patient in a Phase 2b trial of EVO756 for migraine prophylaxis, marking a pivot to a new indication after the drug failed a Phase 2b trial in chronic spontaneous urticaria (CSU) in late June. The trial will enroll approximately 330 patients with refractory migraine and evaluate two dose levels against placebo over 12 weeks, with top-line data expected in 2027. EVO756 is an Mrgprx2 inhibitor. This represents a fresh catalyst for a stock trading near its 52-week low of $10.47, down sharply from the $27.88 private placement price in May. The company's $307 million cash position provides runway through 2028, but the migraine program is now the key value driver following the CSU failure. Success in migraine could open a large market with significant unmet need, but the trial is early and data is years away.
At the time of this announcement, EVMN was trading at $10.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $398M. The 52-week trading range was $10.47 to $33.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.